In early stage NSCLC patients, Markou et al. recently showed correlation between relapse incidence and promoter methylation status of at least one of a five selected genes panel (APC, RASSFIA1, FOXA1, SLFN11, SHOX2) in CTC or plasma-cfDNA (Markou et al., 2022). This evidence concerns the gene SHOX2 and non-small cell lung carcinoma.